By Connor Hart Shares of Jasper Therapeutics rose after the company disclosed what it called positive data from a recent trial of its treatment for chronic mast cell diseases.

“We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,” said Ronald ...

"We are very pleased by the updated results from the SPOTLIGHT study, with briquilimab driving complete responses in over 90% of CIndU participants enrolled in the 180mg cohort,” said Ronald Martell, ...

Investing.com -- Shares of Jasper Therapeutics, Inc. (Nasdaq: JSPR) plummeted over 40% following the release of data from its BEACON study of Briquilimab in Chronic Spontaneous Urticaria (CSU).

“We are very happy to report preliminary data from the BEACON study,” said Ronald Martell, President and Chief Executive Officer of Jasper.

Jasper Therapeutics (JSPR), announced that the first patient has been dosed in Jasper’s Phase 1b/2a clinical challenge study evaluating briquilimab in allergic asthma, called ETESIAN,Evaluating ...

Jasper Therapeutics Announces First Patient Dosed in Phase 1b/2a ETESIAN Clinical Study of Briquilimab in Asthma Dec. 02, 2024 4:30 PM ET Jasper Therapeutics, Inc. (JSPR) ...

The Phase 1b/2a ETESIAN study is a single dose double-blind, placebo-controlled challenge study that is expected to enroll approximately 30 patients across as many as 7 sites in Canada with a key ...

On Tuesday, H.C. Wainwright reaffirmed its Buy rating and $65.00 stock price target for Jasper Therapeutics (NASDAQ:JSPR). The firm's endorsement follows Jasper's recent presentation of six-week data ...

InvestingPro Insights Jasper Therapeutics' (NASDAQ:JSPR) recent positive data from the SPOTLIGHT study aligns with several key insights from InvestingPro.

Jasper also announced that it expects to report initial data from all cohorts of the BEACON study in CSU during the week of January 6 th, 2025, including the recently added 180mg Q8W dose cohort.